期刊文献+

多西紫杉醇联合卡培他滨治疗晚期乳腺癌22例的临床观察 被引量:17

Combination of docetaxel and capecitabine in the treatment of advanced breast cancer
下载PDF
导出
摘要 背景与目的:对于复发转移性乳腺癌,卡培他滨和紫杉醇类药物均有确切肯定的疗效,由于紫杉醇类药物能增强肿瘤组织的TP活性,因而与卡培他滨有协同作用。本研究观察及评价多西紫杉醇联合卡培他滨治疗复发转移性乳腺癌的疗效和不良反应。方法:22例晚期乳腺癌患者均给予多西紫杉醇75 mg/m2,第1天;卡培他滨口服每日2次,餐后服用,1 000 mg/m2/次,连续服用14天,治疗周期为21天,至少治疗2个周期。结果:本组完全缓解(CR)3例,部分缓解(PR)12例,稳定(SD)6例,疾病进展(PD)1例,总有效率68.2%,中位TTP 6.5个月。不同转移部位或器官的有效率分别为:胸壁85.7%(6/7);淋巴结80.0%(8/10);肺脏75.0%(6/8);骨骼40.0%(2/5);肝脏30.0%(3/10)。Ⅰ/Ⅱ级不良反应为皮肤色素沉着16例,手足综合征14例,恶心呕吐12例,腹泻10例,白细胞下降16例。Ⅲ/Ⅳ级不良反应白细胞下降3例,恶心呕吐1例,贫血1例。结论:多西紫杉醇联合卡培他滨治疗晚期乳腺癌疗效肯定,患者耐受性良好。 Background and Purpose: Capecitabine and doeetaxel have been proved to be effective antineoplastic drugs for the treatment of metastatic breast cancer. This study was designed to observe the response rate and toxicity of the combination of docetaxel plus capecitabine for the treatment of metastatic breast cancer. Methods: Twenty-two breast cancer patients who had recurrent and metastatic measurable foci were enrolled into the trial from Dec. 2002 to Dec, 2003. Docetaxel was given at a dose of 75mg/m^2 by intravenous injection at dayl; Capecitabine was orally given at a dose of 2000mg/m^2/d, twice a day for two weeks followed by one week rest with 21 days apart for each cycle, at least two cycles weres given for the patient, Results: Among these 22 patients, the overall response rate was 68, 2% with 3 CR, 12 PR, 6 SD and 1 PD. The median TrP was 6.5 months. Grade Ⅰ-Ⅱ adverse effects were hyperpigmentation in 16(72.7%), hand-foot syndrome in 14 (63.6%), diarrhea in 10 (45.5%), nausea and vomiting in 12 (54.5%) and leukopenia in 16 (72.7%). Side-effect with grade Ⅲ-Ⅳ were anemia in 1 (4.5%), leukopenia in 3(13.6%) and nausea and vomiting in 1 (4.5%). Conclusions: Docetaxel combined with capecitabine is well tolerated and is an efficacious treatment for the patients with advanced breast cancer.
出处 《中国癌症杂志》 CAS CSCD 2006年第3期229-231,共3页 China Oncology
关键词 乳腺肿瘤 多西紫杉醇 卡培他滨 联合化疗 breast cancer docetaxel capecitabine chemotherapy
  • 相关文献

参考文献9

  • 1Burris HA 3rd,Moore MJ,Andersen J,et al.Improvements in survival and clinical bencfit with gemcitabine as first-line therapy for patients with advanced pancreas cancer:a randomized trial[J].J Clin Oncol,1997,15(6):2403-2413.
  • 2江泽飞,宋三泰.紫杉醇在乳腺癌化疗临床应用的新进展[J].中国癌症杂志,2003,13(4):289-292. 被引量:91
  • 3Ravdin PM.Docetaxel (Taxotere) for the treatment of anthracycline-resistant breast cancer[J].Semin Oncol,1997,24(Suppl 10):10-21.
  • 4Valero V,Holmes FA,Walters RS,et al.PhaseⅡ trial of docetaxel:a new,highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer[J].J Clin Oncol,1995,13(12):2886-2894.
  • 5Miwa M,Ura M,Nishida M,et al.Design of a novel oral fluoropyrimidine carbamate,capecitabine,which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue[J].Eur J Cancer,1998,34(8):1274-1281.
  • 6姜丽娜,于世英,熊慧华,张孟贤.胸苷磷酸化酶在癌组织中表达的研究[J].中华肿瘤杂志,2004,26(5):297-299. 被引量:72
  • 7Venturini M,Del Mastro L,Garrone O,et al.Phase I,dose finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer[J].Ann Oncol,2002,13(4):546-552.
  • 8Pronk LC,Vasey P,Sparrboom A,et al.A phase and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumors[J].Br J Cancer,2000,83(1):22-29.
  • 9O' shaughnessy J,miles D,Vukelja S,et al.Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer:phase Ⅲ trial results[J].J Clin Oncol,2002,20(12):2813-2823.

二级参考文献11

  • 1Seidman AD, Tiersten A, Hudis C, et al. Phase Ⅱ trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer [ J ]. J Clin Oncol, 1995,13 ( 10 ) :2575-2581.
  • 2Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HEB2 [ J ]. N Engl J Med,2001,344( 11 ) :783-792.
  • 3Robert N, Leyland-Jones B, Asmar L, et al. Phase Ⅲ comparative study of trastuzumab and paclitaxel with and without carbeplatin in patients with HER-2/neu positive advanced breast cancer[J]. Breast Cancer Res Treat,2002,76(supple) :37.
  • 4Seidman AD, Fornier MN, Esteva FJ, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplificanton[ J ]. J Clin Oncol,2001,19 (10) :2587-2595.
  • 5Early Breast Cancer Trialists " Collaborative Group,Polychemotherapy for early breast cancer: an overview of the randomised trials [ J ]. Lancet, 1998,352 (2) :930-934.
  • 6Henderson C, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer[ J ]. J Clin Oncol, 2003,21 ( 6 ) :976-983.
  • 7Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741[J]. J Clin Oncol,2003,21 (8) :1431-1439.
  • 8Hiroyuki Eda,Kaori Fujimoto,Shin-ichi Watanabe,Masako Ura,Ayako Hino,Yutaka Tanaka,Kenji Wada,Hideo Ishitsuka. Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5′-deoxy-5-fluorouridine[J] 1993,Cancer Chemotherapy and Pharmacology(5):333~338
  • 9江泽飞,宋三泰,刘晓晴,徐建明,李彦博,李家益.单用国产紫杉醇治疗乳腺癌[J].中华肿瘤杂志,1997,19(6):445-447. 被引量:21
  • 10李捷,宋三泰,江泽飞,刘晓晴,颜玲娣.血管内皮生长因子及微血管密度在乳腺癌中的表达及意义[J].中华肿瘤杂志,2003,25(2):145-147. 被引量:36

共引文献160

同被引文献86

引证文献17

二级引证文献54

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部